TRI-LO-MILI Drug Patent Profile

« Back to Dashboard

Which patents cover Tri-lo-mili, and when can generic versions of Tri-lo-mili launch?

Tri-lo-mili is a drug marketed by Aurobindo Pharma and is included in one NDA.

The generic ingredient in TRI-LO-MILI is ethinyl estradiol; norgestimate. There is one drug master file entry for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norgestimate profile page.

Summary for TRI-LO-MILI

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
DailyMed Link:	TRI-LO-MILI at DailyMed

US Patents and Regulatory Information for TRI-LO-MILI

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aurobindo Pharma	TRI-LO-MILI	ethinyl estradiol; norgestimate	TABLET;ORAL-28	205762-001	Nov 4, 2016	AB	RX	No	No

TRI-LO-MILI Market Dynamics and Financial Trajectory

Last updated: August 31, 2026

TRI-LO-MILI is a generic triphasic oral contraceptive containing norgestimate and ethinyl estradiol. Its commercial outlook is driven by prescription volume, payer substitution, generic price erosion, manufacturing reliability, and competition from other combined oral contraceptives. The product has limited standalone financial transparency because Glenmark does not publicly report TRI-LO-MILI revenue, margin, prescription share, or inventory by product.

What is TRI-LO-MILI and who manufactures it?

TRI-LO-MILI is a 28-day prescription oral contraceptive supplied in three hormone strengths. Each active tablet contains ethinyl estradiol 0.025 mg with norgestimate at 0.18 mg, 0.215 mg, or 0.25 mg, depending on the week of the cycle. The product has 21 active tablets and seven inert tablets.[1]

Attribute	TRI-LO-MILI profile
Active ingredients	Norgestimate and ethinyl estradiol
Dosage form	Oral tablet
Regimen	21 active tablets followed by seven inert tablets
Therapeutic category	Combined hormonal contraceptive
FDA pathway	Abbreviated New Drug Application, or ANDA
Reference-product class	Ortho Tri-Cyclen Lo and equivalent norgestimate/ethinyl estradiol products
Primary U.S. commercial supplier	Glenmark Pharmaceuticals
Biosimilar status	Not applicable
Prescription status	Prescription-only

TRI-LO-MILI is approved to prevent pregnancy. Its label carries the class risks associated with estrogen-containing contraceptives, including venous thromboembolism and arterial thrombotic events in higher-risk patients.[1]

The product competes primarily on generic availability, formulary placement, pharmacy inventory, and wholesale acquisition cost rather than on clinical differentiation.

What is the FDA regulatory status of TRI-LO-MILI?

TRI-LO-MILI is an FDA-approved generic oral contraceptive. FDA approval under the ANDA pathway requires the generic product to demonstrate pharmaceutical equivalence and bioequivalence to the reference product. The approval pathway does not require a new clinical efficacy program comparable to an innovator application.[2]

The product is not a biologic and has no biosimilar exposure. Regulatory risk is therefore concentrated in:

• Manufacturing compliance.
• Product-quality investigations.
• Supply continuity.
• Labeling changes.
• Bioequivalence or stability documentation.
• FDA inspection findings at manufacturing or testing facilities.

The product’s commercial status depends on the continued availability of an approved ANDA and the ability to maintain adequate supply to wholesalers, pharmacy benefit managers, retail pharmacies, and public-sector purchasers.

What patents protect TRI-LO-MILI?

TRI-LO-MILI is a mature generic product with limited apparent patent-based exclusivity. The principal commercial barrier is no longer an active innovator patent estate around the original oral contraceptive concept. Generic manufacturers entered after expiration or resolution of the relevant patent and regulatory exclusivity barriers surrounding the reference-product class.

The relevant intellectual-property categories are:

IP category	Relevance to TRI-LO-MILI
Active-ingredient patents	Mature and generally expired for the norgestimate/ethinyl estradiol combination
Basic formulation patents	Limited commercial significance for a standard tablet
Method-of-use patents	Unlikely to prevent ordinary contraceptive use of the approved generic
Manufacturing patents	Could affect specific processes but generally do not block ordinary generic entry
Packaging or delivery patents	Low relevance because TRI-LO-MILI is a conventional oral tablet
Orange Book-listed patents	The current FDA Orange Book record controls any active listing and litigation implications

The product does not depend on a proprietary delivery system, extended-release platform, transdermal system, implant, or device. That reduces formulation-based differentiation and makes substitution easier.

When does TRI-LO-MILI lose exclusivity?

TRI-LO-MILI did not receive the type of new-drug market exclusivity associated with an innovative NDA. Its commercial protection is based on generic approval, supplier relationships, manufacturing scale, and market access.

The relevant exclusivity timeline is:

Event	Commercial effect
Original innovator approval	Established the norgestimate/ethinyl estradiol product class
Patent and regulatory exclusivity expiry	Opened the market to ANDA applicants
Generic approvals	Increased substitution and reduced price
Multiple-supplier availability	Increased pharmacy and payer leverage
Ongoing generic competition	Sustains price pressure

Generic entry risk is therefore immediate in structural terms. The product is already exposed to competition from equivalent or therapeutically substitutable products.

Are there Paragraph IV challenges involving TRI-LO-MILI?

Paragraph IV litigation is generally associated with an ANDA applicant challenging an unexpired patent listed for a reference product. TRI-LO-MILI is a marketed generic rather than a protected innovator product, so it is not normally the focal point of a Paragraph IV challenge.

The more relevant litigation scenarios would involve:

1. A patent dispute concerning another norgestimate/ethinyl estradiol formulation.
2. A manufacturing or quality dispute.
3. A product-liability claim.
4. A trade-secret or process dispute between generic manufacturers.
5. A regulatory challenge involving approval, labeling, or manufacturing compliance.

No widely reported, product-defining Paragraph IV litigation is associated with TRI-LO-MILI in the public record available for this analysis. The FDA Orange Book and federal court filings remain the controlling sources for any later-listed patent or litigation development.[3]

What formulations are protected by TRI-LO-MILI patents?

TRI-LO-MILI uses a conventional oral tablet formulation. Its principal formulation characteristic is the sequential variation in norgestimate content across the three active-tablet phases, while ethinyl estradiol remains at the same nominal strength.

The formulation has limited defensibility because:

• The dosage form is a standard tablet.
• The active ingredients are established molecules.
• The product does not use a proprietary device.
• The regimen can be supplied by competing generic manufacturers.
• Prescribers and pharmacies can substitute among equivalent products when permitted by state law and payer rules.

A competitor does not need to reproduce the brand name or packaging. It must satisfy FDA equivalence requirements and secure commercial distribution.

How strong is the TRI-LO-MILI patent estate?

The patent estate is weak as a source of exclusivity and moderate only as a compliance and manufacturing asset.

Patent-strength factor	Assessment
Composition-of-matter protection	Weak or expired
New chemical entity protection	Not applicable
Formulation differentiation	Limited
Device protection	None apparent
Method-of-use protection	Limited practical effect
Manufacturing know-how	Potentially relevant but difficult to assess publicly
Regulatory exclusivity	Generic pathway; no meaningful innovator exclusivity
Substitution resistance	Low
Litigation leverage	Low absent a new patent or regulatory dispute

The primary economic moat is operational rather than legal. A supplier that maintains reliable inventory, competitive pricing, acceptable fill rates, and favorable pharmacy contracts can retain business despite limited patent protection.

How does TRI-LO-MILI compare with competing contraceptives?

TRI-LO-MILI competes across several product groups rather than against one direct rival.

Product group	Examples	Competitive relationship
Same active ingredients	Generic norgestimate/ethinyl estradiol products	Closest substitutes
Other combined pills	Levonorgestrel/ethinyl estradiol, norethindrone/ethinyl estradiol	Therapeutic substitutes
Progestin-only pills	Norethindrone, drospirenone products	Alternative for selected patients
Long-acting contraception	IUDs, implants, injections	Compete for contraceptive demand but not usually pharmacy substitution
Branded oral contraceptives	Brand and authorized-generic products	Compete on preference, coverage, and promotional positioning

TRI-LO-MILI has a cost advantage over branded oral contraceptives but little clinical differentiation from other generic combined pills. Switching can occur at the pharmacy level when the product is designated therapeutically equivalent and the payer allows substitution.

What market dynamics affect TRI-LO-MILI sales?

The U.S. oral contraceptive market is mature and highly substitutable. Demand is relatively stable because contraception is a recurring-use category, but individual-product revenue can fluctuate substantially.

Payer and pharmacy pressure

Commercial payers and pharmacy benefit managers typically favor low-cost generic products. Preferred formulary status can increase volume, while nonpreferred status can materially reduce dispensing even when the product remains FDA approved.

Retail pharmacies also manage inventory by limiting the number of equivalent products stocked at each location. A product can lose share because of wholesaler allocation, back-order status, contract changes, or replacement by another generic with a lower acquisition cost.

Supply and manufacturing

Supply continuity is central to TRI-LO-MILI’s economics. Oral contraceptive manufacturers face exposure to:

• Active pharmaceutical ingredient availability.
• Contract manufacturing capacity.
• Packaging-component supply.
• FDA inspection outcomes.
• Recalls and quality investigations.
• Wholesale inventory requirements.
• Seasonal and public-sector procurement patterns.

A supply interruption can temporarily increase demand for substitute products, but the resulting volume may not persist after competing inventory returns.

Prescriber behavior

Prescriber loyalty is weaker for a generic oral contraceptive than for a branded specialty drug. Prescribers often select the contraceptive class and clinical profile, while the pharmacy or payer determines the dispensed manufacturer.

This structure limits the value of promotional spending and increases the importance of contracting, distribution, and product availability.

What is the financial trajectory of TRI-LO-MILI?

TRI-LO-MILI’s likely financial trajectory is characterized by stable or modestly growing unit demand but declining price per prescription over the long term.

Financial driver	Expected effect
Contraceptive demand	Supports recurring prescription volume
Generic competition	Reduces net price
Formulary preference	Can increase or reduce volume quickly
Manufacturing scale	Determines gross-margin resilience
Supply shortages	Can create temporary volume upside
Pharmacy substitution	Limits brand-level pricing power
Product differentiation	Minimal
Public-sector purchasing	Adds volume but increases price pressure

Glenmark’s public financial reporting does not separately disclose TRI-LO-MILI revenue or operating profit. The product therefore cannot be assigned a verified standalone revenue forecast from company filings. Glenmark reports at broader geographic or business-segment levels, leaving product-level sales, gross margin, and market share unavailable in public filings.[4]

The most likely commercial pattern is:

1. Early post-launch growth as pharmacies add the product to generic inventories.
2. Price compression as additional suppliers enter.
3. Volume stabilization if the product obtains durable payer and wholesaler access.
4. Margin pressure from lower reimbursement and manufacturing costs.
5. Periodic volume changes caused by shortages or competitor exits.
6. Mature-market revenue based primarily on prescription throughput rather than price increases.

TRI-LO-MILI is unlikely to be a major company-level revenue driver unless it holds unusually strong distribution contracts or benefits from a sustained competitor shortage.

What generic launch risks exist for TRI-LO-MILI?

The main generic launch risk is not a future launch against TRI-LO-MILI’s patent estate. It is displacement by another equivalent product.

Potential competitive events include:

• A lower-priced generic gaining preferred formulary status.
• A competitor restoring supply after a shortage.
• A pharmacy chain switching its preferred manufacturer.
• An authorized generic entering through a commercial partnership.
• A rival product receiving broader distribution.
• A manufacturing issue causing a temporary or permanent withdrawal.

Because the product is interchangeable at the therapeutic-class level, a competitor can reduce TRI-LO-MILI prescriptions without demonstrating superior clinical outcomes.

What licensing deals affect TRI-LO-MILI?

No major publicly disclosed licensing transaction is identified as a central commercial driver of TRI-LO-MILI. Generic oral contraceptives can be commercialized through contract manufacturing, supply agreements, distribution arrangements, or authorized-generic structures without creating a high-profile branded licensing model.

The economically relevant agreements are likely to be private arrangements involving:

• API sourcing.
• Finished-dose manufacturing.
• Packaging.
• Wholesale distribution.
• Pharmacy benefit manager access.
• Government procurement.
• Authorized-generic supply.

These agreements are generally not disclosed at the individual-product level.

What is the geographic coverage of TRI-LO-MILI?

TRI-LO-MILI is primarily a U.S. product. Its addressable market is determined by U.S. FDA approval, payer coverage, pharmacy distribution, and state-level substitution rules.

International markets may contain equivalent norgestimate/ethinyl estradiol products under different brand names, regulatory approvals, and manufacturers. Those products should not be treated as TRI-LO-MILI revenue unless they are supplied under the same commercial authorization and reported by the same entity.

Key Takeaways

• TRI-LO-MILI is a generic norgestimate/ethinyl estradiol oral contraceptive marketed by Glenmark.
• It has no apparent durable patent-based pricing protection.
• Biosimilar competition is irrelevant because the product is a small-molecule tablet.
• Revenue is driven by prescription volume, payer preference, pharmacy substitution, and supply reliability.
• Glenmark does not publicly disclose TRI-LO-MILI-specific revenue or profit.
• The expected long-term pattern is stable demand, declining net price, and margin sensitivity.
• The principal competitive risk is displacement by another equivalent generic, not a conventional Paragraph IV challenge.
• Manufacturing, distribution, and formulary access are more important than patent exclusivity.

FAQs About TRI-LO-MILI Market and Financial Outlook

Is TRI-LO-MILI a brand-name drug or a generic?

TRI-LO-MILI is a generic prescription oral contraceptive containing norgestimate and ethinyl estradiol.

Is TRI-LO-MILI interchangeable with Ortho Tri-Cyclen Lo?

FDA therapeutic-equivalence determinations and state substitution rules control interchangeability. TRI-LO-MILI was developed as a generic equivalent within the same product class, but pharmacy substitution depends on the applicable FDA and state requirements.

Does TRI-LO-MILI have biosimilar competition?

No. Biosimilar regulation applies to biologic products. TRI-LO-MILI is a chemically synthesized small-molecule tablet.

Can TRI-LO-MILI revenue be calculated from Glenmark’s annual reports?

Not reliably. Glenmark reports financial results at broader business and geographic levels and does not separately disclose TRI-LO-MILI revenue, prescription volume, or product margin.[4]

What would most improve TRI-LO-MILI’s commercial performance?

The strongest commercial levers are preferred formulary placement, reliable supply, competitive net pricing, broad wholesaler access, and avoidance of quality or manufacturing interruptions.

References

1. DailyMed. (n.d.). Tri-Lo-Mili: Norgestimate and ethinyl estradiol tablets prescribing information. U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (n.d.). Generic drug facts. https://www.fda.gov/drugs/generic-drugs/generic-drug-facts

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. Glenmark Pharmaceuticals. (2024). Annual report and financial results. Glenmark Pharmaceuticals Limited.